Provided by Tiger Trade Technology Pte. Ltd.

Aclaris Therapeutics

6.41
+0.08001.26%
Pre-market: 6.450.0400+0.62%06:00 EDT
Volume:2.21M
Turnover:14.18M
Market Cap:943.54M
PE:-10.94
High:6.50
Open:6.36
Low:6.29
Close:6.33
52wk High:6.52
52wk Low:1.74
Shares:147.20M
Float Shares:110.00M
Volume Ratio:1.50
T/O Rate:2.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5861
EPS(LYR):-0.5300
ROE:-59.10%
ROA:-28.98%
PB:7.57
PE(LYR):-12.09

Loading ...

Aclaris Therapeutics Enters Amended At-the-Market Equity Sales Agreement with Leerink, Cantor

Reuters
·
Aug 07

Aclaris Says FDA Grants Fast Track Status for Modzatinib in Moderate to Severe Lichen Planus

Reuters
·
Aug 07

Aclaris Therapeutics Gets Fast-Track Designation for Inflammation Treatment Modzatinib

Dow Jones
·
Aug 07

Aclaris Therapeutics receives FDA Fast Track Designation for Modzatinib

TIPRANKS
·
Aug 07

Aclaris Therapeutics, Inc. Files for Mixed Shelf; Size not Disclosed - SEC Filing

THOMSON REUTERS
·
Aug 07

Aclaris Therapeutics, Inc.: Expects to Initiate a Phased Multi-Part Phase 2B Trial of Modzatinib in Lp in Q4 of 2026

THOMSON REUTERS
·
Aug 07

Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (Lp)

THOMSON REUTERS
·
Aug 07

Craig-Hallum Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)

TIPRANKS
·
Aug 06

Aclaris Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Aclaris Q2 FY26 Net Loss Widens to $21.5 Million; Revenue Slips to $1.6 Million

Reuters
·
Aug 06

Aclaris Therapeutics Q2 Revenue Beats Analyst Estimates

Reuters
·
Aug 06

Earnings Flash (ACRS) Aclaris Therapeutics Posts Q2 Net Loss $0.15 a Share, vs. FactSet Est of $0.16 Loss

MT Newswires Live
·
Aug 06

Aclaris Therapeutics Q2 EPS $(0.15) Beats $(0.16) Estimate, Sales $1.629M Beat $1.383M Estimate

Benzinga Earnings
·
Aug 06

Aclaris Therapeutics, - Expects Cash to Fund Operations Through End of 2028

THOMSON REUTERS
·
Aug 06

Aclaris Therapeutics Q2 Net Income USD -21.505 Million VS. Ibes Estimate USD -21.3 Million

THOMSON REUTERS
·
Aug 06

Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update

THOMSON REUTERS
·
Aug 06

Aclaris Therapeutics Inc Expected to Post a Loss of 16 Cents a Share - Earnings Preview

Reuters
·
Aug 03

Aclaris Publishes Corporate Presentation Outlining Inflammatory and Immunology Pipeline, 2026 Clinical Catalysts

Reuters
·
Jul 16

Aclaris Therapeutics management to meet with Oppenheimer

TIPRANKS
·
Jun 17

Aclaris Therapeutics stockholders approve 2026 executive pay plan in advisory vote

Reuters
·
Jun 05